<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

AACR 2023 Poster 579

Mini-tumors: Pre-clinical HCI assays to screen anti-cancer drugs in the context of organoids, cancer-associated fibroblasts and immune cells

Marten Hornsveld, Cyrelle van Dort, Guusje Odenkirchen, Jara Garcia, Saskia de Man, Nataliia Beztsinna, Gera Goverse, Bram Herpers, Mariusz Madej, Leo Price, Marrit Putker

Effective drug development relies on representative preclinical models to discover and characterize novel cancer therapies. Recapitulating the human specific tumor microenvironment (TME) is essential for immuno-oncology studies or TME-targeting agents and the detection of human-specific (off-)target effects to better predict therapeutic response and clinical outcomes.In this study, a preclinical platform for drug testing is presented, consisting of organotypic mini-tumors combined with highcontent imaging screening (HCI) to discriminate different cell types and assess morphological, cytostatic and cytotoxic effects of drugs simultaneously.

Download this Poster to Discover:

  • A novel high content imaging platform to test drugs within the context of a reconstituted TME.

  • A versatile platform capable of including tumor organoids of interest, fibroblasts and immune cells e.g. T cells, Monocytes, M1 and M2 macrophages.

  • How fibroblasts represent the myofibroblast subpopulation, support tumor growth and confer SoC drug resistance

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.